Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), NewAmsterdam Pharma Company (NAMS) and Surgery Partners (SGRY)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EyePoint Pharmaceuticals (EYPT)
RBC Capital analyst Lisa Walter maintained a Buy rating on EyePoint Pharmaceuticals on August 6 and set a price target of $28.00. The company's shares closed last Thursday at $10.07.
According to TipRanks.com, Walter is ranked 0 out of 5 stars with an average return of -15.9% and a 47.6% success rate. Walter covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Adverum Biotechnologies, and Apellis Pharmaceuticals.
Currently, the analyst consensus on EyePoint Pharmaceuticals is a Strong Buy with an average price target of $26.71, representing a 147.1% upside. In a report issued on July 29, Mizuho Securities also maintained a Buy rating on the stock with a $26.00 price target.
NewAmsterdam Pharma Company (NAMS)
RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company on August 6 and set a price target of $39.00. The company's shares closed last Thursday at $22.96.
According to TipRanks.com, Timashev is a 3-star analyst with an average return of 4.7% and a 44.1% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Edgewise Therapeutics, and Jazz Pharmaceuticals.
NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $48.18, a 103.0% upside from current levels. In a report issued on July 30, Cantor Fitzgerald also maintained a Buy rating on the stock with a $42.00 price target.
Surgery Partners (SGRY)
In a report issued on August 6, Ben Hendrix from RBC Capital maintained a Buy rating on Surgery Partners, with a price target of $35.00. The company's shares closed last Thursday at $23.22.
According to TipRanks.com, Hendrix is a 3-star analyst with an average return of 1.1% and a 48.5% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Aveanna Healthcare Holdings, and Brookdale Senior Living.
Currently, the analyst consensus on Surgery Partners is a Moderate Buy with an average price target of $30.90, which is a 36.5% upside from current levels. In a report issued on August 5, TD Cowen also reiterated a Buy rating on the stock with a $28.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
8 hours ago
- Business Insider
Analysts Offer Insights on Financial Companies: ASX (OtherASXFF) and Toronto Dominion Bank (TD)
Companies in the Financial sector have received a lot of coverage today as analysts weigh in on ASX (ASXFF – Research Report) and Toronto Dominion Bank (TD – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. ASX (ASXFF) In a report released today, Nigel Pittaway from Citi maintained a Hold rating on ASX, with a price target of A$71.60. The company's shares closed last Thursday at $46.39. According to Pittaway is a 3-star analyst with an average return of 3.6% and a 55.9% success rate. Pittaway covers the Financial sector, focusing on stocks such as Insurance Australia Group Limited, QBE Insurance Group Limited, and Computershare Limited. Currently, the analyst consensus on ASX is a Hold with an average price target of $44.82, a -3.4% downside from current levels. In a report issued on August 8, J.P. Morgan also maintained a Hold rating on the stock with a A$67.50 price target. Jefferies analyst John Aiken maintained a Buy rating on Toronto Dominion Bank yesterday and set a price target of C$117.00. The company's shares closed last Wednesday at $74.48. According to Aiken is a 2-star analyst with an average return of 0.4% and a 51.5% success rate. Aiken covers the Financial sector, focusing on stocks such as Canadian Bank of Commerce, National Bank of Canada, and Royal Bank Of Canada. Toronto Dominion Bank has an analyst consensus of Moderate Buy, with a price target consensus of $73.71, implying a -0.2% downside from current levels. In a report issued on August 12, Desjardins also upgraded the stock to Buy with a C$107.00 price target.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Technology Companies: Paychex (PAYX) and TaskUs (TASK)
Analysts fell to the sidelines weighing in on Paychex (PAYX – Research Report) and TaskUs (TASK – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Paychex (PAYX) RBC Capital analyst Ashish Sabadra maintained a Hold rating on Paychex on August 8 and set a price target of $150.00. The company's shares closed last Tuesday at $134.99. According to Sabadra is a 5-star analyst with an average return of 6.2% and a 61.6% success rate. Sabadra covers the Financial sector, focusing on stocks such as Intercontinental Exchange, Cboe Global Markets, and Factset Research. Currently, the analyst consensus on Paychex is a Hold with an average price target of $149.64. TaskUs (TASK) In a report issued on August 8, Daniel Perlin from RBC Capital maintained a Hold rating on TaskUs, with a price target of $16.50. The company's shares closed last Tuesday at $17.03. According to Perlin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.7% and a 35.8% success rate. Perlin covers the Technology sector, focusing on stocks such as Broadridge Financial Solutions, SS&C Technologies Holdings, and TELUS International (CDA). TaskUs has an analyst consensus of Hold, with a price target consensus of $18.00, representing a 5.5% upside. In a report issued on August 8, Guggenheim also maintained a Hold rating on the stock.
Business Insider
a day ago
- Business Insider
Analysts Have Conflicting Sentiments on These Utilities Companies: Uniper (OtherUNPRF) and AGL Energy (OtherAGLNF)
Companies in the Utilities sector have received a lot of coverage today as analysts weigh in on Uniper (UNPRF – Research Report) and AGL Energy (AGLNF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Uniper (UNPRF) In a report issued on August 11, Ingo Becker from Kepler Capital maintained a Sell rating on Uniper, with a price target of EUR30.00. The company's shares closed last Friday at $40.16, close to its 52-week low of $39.60. Becker has an average return of 5.7% when recommending Uniper. According to Becker is ranked #816 out of 9951 analysts. Uniper has an analyst consensus of Moderate Sell, with a price target consensus of $34.86. AGL Energy (AGLNF) UBS analyst Tom Allen maintained a Hold rating on AGL Energy today and set a price target of A$11.50. The company's shares closed last Tuesday at $6.65. Allen has an average return of 24.7% when recommending AGL Energy . According to Allen is ranked #1456 out of 9951 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AGL Energy with a $7.64 average price target, implying a 14.9% upside from current levels. In a report issued on August 8, Morgan Stanley also maintained a Hold rating on the stock with a A$11.88 price target.
